A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. (Q44963311)
Jump to navigation
Jump to search
scientific article published on 26 June 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. |
scientific article published on 26 June 2013 |
Statements
1 reference
A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. (English)
1 reference
B Melichar
1 reference
S Bracarda
1 reference
V Matveev
1 reference
B Alekseev
1 reference
S Ivanov
1 reference
A Zyryanov
1 reference
R Janciauskiene
1 reference
E Fernebro
1 reference
P Mulders
1 reference
S Osborne
1 reference
S Jethwa
1 reference
G Mickisch
1 reference
M Gore
1 reference
R J A van Moorselaar
1 reference
M Staehler
1 reference
N Magne
1 reference
J Bellmunt
1 reference
BEVLiN Investigators
1 reference
26 June 2013
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference